All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Did you miss ASH 2018? The Multiple Myeloma Hub attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA and has developed a downloadable resource, which provides information on the practice changing abstracts across multiple myeloma (MM).
Our selection of ASH abstracts includes comments from the MM Hub Steering Committee on the key phase III clinical trials presented during ASH, such as TOURMALINE-MM3 and Alycone, as well as the results from the pivotal study of selinexor with dexamethasone in penta-refractory MM and the first reports on the effect of melflufen treatment on progression free survival.
ASH 2018 | Practice changing abstracts in multiple myeloma
If you would like to view the ASH 2018 highlights, practice changing abstracts and expert opinions please find the Multiple Myeloma Hub resource below
Download HereSubscribe to get the best content related to multiple myeloma delivered to your inbox